Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Transjugular Intrahepatic Portosystemic Shunt

Research Leaders

6 sponsors active, led by Shi Yun

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Early Phase 1 (1)

Trial Status

Recruiting1
Not Yet Recruiting1
Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT06794853Recruiting

Mechanism of TIPS to Improve Sarcopenia

NCT07161167Not Yet Recruiting

Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study

NCT06102655Early Phase 1Completed

Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics

NCT04833881UnknownPrimary

Proteomics/Modifier Based on Mass Spectrometry Reveals the Pathogenesis of Eclampsia During Pregnancy and the Screening of Disease Markers

Showing all 4 trials

Research Network

Common Treatments

  • Transjugular Intrahepatic Portosystemic Shunt1
  • Jiajian Guishen Formulation1

Active Sponsors

  • Shi Yun1
  • Heilongjiang University of Chinese Medicine1
  • The First Affiliated Hospital of Henan University of Science and Technology1
  • Peking Union Medical College Hospital1
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1

Top Investigators

Related Conditions

  • Marker Screening1
  • Cirrhosis1
  • Metabolomics1
  • Clinical Syndrome1
  • Sarcopenia1

Activity Timeline